Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Warren Fiskus; Naval Daver; Steffen Boettcher; Christopher P. Mill; Koji Sasaki; Christine E. Birdwell; John A. Davis; Kaberi Das; Koichi Takahashi; Tapan M. Kadia; Courtney D. DiNardo; Francis Burrows; Sanam Loghavi; Joseph D. Khoury; Benjamin L. Ebert; Kapil N. Bhalla

doi:10.1038/s41375-022-01707-w

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Warren Fiskus, Naval Daver, Steffen Boettcher, Christopher P. Mill, Koji Sasaki, Christine E. Birdwell, John A. Davis, Kaberi Das, Koichi Takahashi, Tapan M. Kadia, Courtney D. DiNardo, Francis Burrows, Sanam Loghavi, Joseph D. Khoury, Benjamin L. Ebert, Kapil N. Bhalla

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Original language	English (US)
Pages (from-to)	2729-2733
Number of pages	5
Journal	Leukemia
Volume	36
Issue number	11
DOIs	https://doi.org/10.1038/s41375-022-01707-w
State	Published - Nov 2022
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-022-01707-w

Cite this

Fiskus, W., Daver, N., Boettcher, S., Mill, C. P., Sasaki, K., Birdwell, C. E., Davis, J. A., Das, K., Takahashi, K., Kadia, T. M., DiNardo, C. D., Burrows, F., Loghavi, S., Khoury, J. D., Ebert, B. L., & Bhalla, K. N. (2022). Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia, 36(11), 2729-2733. https://doi.org/10.1038/s41375-022-01707-w

Fiskus, W, Daver, N, Boettcher, S, Mill, CP, Sasaki, K, Birdwell, CE, Davis, JA, Das, K, Takahashi, K, Kadia, TM, DiNardo, CD, Burrows, F, Loghavi, S, Khoury, JD, Ebert, BL & Bhalla, KN 2022, 'Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1', Leukemia, vol. 36, no. 11, pp. 2729-2733. https://doi.org/10.1038/s41375-022-01707-w

@article{c5f9cbcf833a4b418bd72dd4521a53dd,

title = "Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1",

author = "Warren Fiskus and Naval Daver and Steffen Boettcher and Mill, {Christopher P.} and Koji Sasaki and Birdwell, {Christine E.} and Davis, {John A.} and Kaberi Das and Koichi Takahashi and Kadia, {Tapan M.} and DiNardo, {Courtney D.} and Francis Burrows and Sanam Loghavi and Khoury, {Joseph D.} and Ebert, {Benjamin L.} and Bhalla, {Kapil N.}",

note = "Funding Information: The authors would like to thank the Sequencing and Microarray Core Facility, Flow Cytometry and Cellular Imaging (FCCI) Core Facility, which are supported by the MD Anderson Cancer Center Support Grant 5 P30 CA016672-40. KNB was supported by a grant from the NIH (R01 CA255721). This research is supported in part by the MD Anderson Cancer Center Leukemia SPORE (P50 CA100632). ",

year = "2022",

month = nov,

doi = "10.1038/s41375-022-01707-w",

language = "English (US)",

volume = "36",

pages = "2729--2733",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

AU - Fiskus, Warren

AU - Daver, Naval

AU - Boettcher, Steffen

AU - Mill, Christopher P.

AU - Sasaki, Koji

AU - Birdwell, Christine E.

AU - Davis, John A.

AU - Das, Kaberi

AU - Takahashi, Koichi

AU - Kadia, Tapan M.

AU - DiNardo, Courtney D.

AU - Burrows, Francis

AU - Loghavi, Sanam

AU - Khoury, Joseph D.

AU - Ebert, Benjamin L.

AU - Bhalla, Kapil N.

N1 - Funding Information: The authors would like to thank the Sequencing and Microarray Core Facility, Flow Cytometry and Cellular Imaging (FCCI) Core Facility, which are supported by the MD Anderson Cancer Center Support Grant 5 P30 CA016672-40. KNB was supported by a grant from the NIH (R01 CA255721). This research is supported in part by the MD Anderson Cancer Center Leukemia SPORE (P50 CA100632).

PY - 2022/11

Y1 - 2022/11

UR - http://www.scopus.com/inward/record.url?scp=85138733590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138733590&partnerID=8YFLogxK

U2 - 10.1038/s41375-022-01707-w

DO - 10.1038/s41375-022-01707-w

M3 - Article

C2 - 36151141

AN - SCOPUS:85138733590

SN - 0887-6924

VL - 36

SP - 2729

EP - 2733

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this